MX2013006170A - Formulaciones virales liquidas. - Google Patents
Formulaciones virales liquidas.Info
- Publication number
- MX2013006170A MX2013006170A MX2013006170A MX2013006170A MX2013006170A MX 2013006170 A MX2013006170 A MX 2013006170A MX 2013006170 A MX2013006170 A MX 2013006170A MX 2013006170 A MX2013006170 A MX 2013006170A MX 2013006170 A MX2013006170 A MX 2013006170A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- liquid
- viral formulations
- liquid viral
- viral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12251—Methods of production or purification of viral material
Abstract
En la presente se proporcionan formulaciones virales líquidas útiles para la estabilización y almacenamiento de virus y métodos para preparar estas formulaciones. Las formulaciones virales líquidas descritas en la presente incluyen un virus (por ej., un virus purificado) y una composición no viral incluyendo excipientes y un portador líquido. Las formulaciones se pueden usar, por ejemplo, para conservar la infectividad o inmunogenicidad de los virus durante períodos de almacenamiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41903210P | 2010-12-02 | 2010-12-02 | |
PCT/US2011/063040 WO2012075379A2 (en) | 2010-12-02 | 2011-12-02 | Liquid viral formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013006170A true MX2013006170A (es) | 2013-12-02 |
MX350932B MX350932B (es) | 2017-09-26 |
Family
ID=46162439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013006170A MX350932B (es) | 2010-12-02 | 2011-12-02 | Formulaciones virales liquidas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US9045728B2 (es) |
EP (1) | EP2646051A4 (es) |
JP (4) | JP6034798B2 (es) |
KR (1) | KR101875245B1 (es) |
CN (1) | CN103347535B (es) |
AU (1) | AU2011336413B2 (es) |
CA (1) | CA2819246C (es) |
EA (1) | EA201390810A1 (es) |
IL (1) | IL226647A (es) |
MX (1) | MX350932B (es) |
SG (1) | SG190418A1 (es) |
TW (1) | TW201233802A (es) |
WO (1) | WO2012075379A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101647843B1 (ko) * | 2007-03-12 | 2016-08-11 | 온콜리틱스 바이오테크 인코포레이티드 | 변형된 서열을 갖는 레오바이러스 |
SG190419A1 (en) | 2010-12-02 | 2013-06-28 | Oncolytics Biotech Inc | Lyophilized viral formulations |
AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
MX337348B (es) * | 2011-04-29 | 2016-02-29 | Oncolytics Biotech Inc | Metodos para purificar virus utilizando cromatografia de permeacion en gel. |
US9649279B2 (en) | 2013-12-16 | 2017-05-16 | Massachusetts Institute Of Technology | Fortified micronutrient salt formulations |
AU2014364930B2 (en) * | 2013-12-16 | 2017-06-15 | Massachusetts Institute Of Technology | Micromolded or 3-D printed pulsatile release vaccine formulations |
WO2018204677A1 (en) * | 2017-05-04 | 2018-11-08 | Epicentrx, Inc. | Oncolytic adenovirus formulation |
KR101906732B1 (ko) * | 2017-07-21 | 2018-10-10 | 유지훈 | 바지 다림질 장치용 바지 스프레딩 장치 |
AU2018378590A1 (en) * | 2017-12-05 | 2020-06-25 | Beacon Therapeutics Limited | Formulation optimization for viral particles |
CN113350344A (zh) * | 2020-03-06 | 2021-09-07 | 华南理工大学 | 左旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用 |
CN113350343A (zh) * | 2020-03-06 | 2021-09-07 | 华南理工大学 | 右旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用 |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2505657A1 (fr) | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
US5626851A (en) | 1987-11-30 | 1997-05-06 | The Wistar Institute Of Anatomy And Biology | Rotavirus reassortant vaccine |
US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
ATE148165T1 (de) | 1989-07-24 | 1997-02-15 | Bayer Ag | Stabilisierung von hochgereinigten proteinen |
EP0713397B1 (en) | 1992-03-24 | 2002-12-11 | United Cancer Research Institute | Vaccine containing live virus |
CA2075521C (en) | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Stabilized live vaccine |
CA2158935A1 (en) | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
ATE328068T1 (de) | 1994-05-16 | 2006-06-15 | Merck & Co Inc | Papillomavirus vakzine |
US7150984B2 (en) | 1994-07-11 | 2006-12-19 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated human rotavirus vaccine |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
JPH11510170A (ja) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9521806D0 (en) | 1995-10-25 | 1996-01-03 | Cortecs Ltd | Preservation methods |
US6165773A (en) | 1995-10-25 | 2000-12-26 | Provalis Uk Limited | Methods of preserving viruses |
FR2742756B1 (fr) | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
US5932223A (en) * | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
US6403098B1 (en) | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
DK0939648T3 (da) | 1996-09-26 | 2008-02-11 | Merck & Co Inc | Rotavirusvaccineformuleringer |
US6616931B1 (en) | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6544769B1 (en) | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
US20080261289A1 (en) | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
US6051238A (en) | 1996-12-20 | 2000-04-18 | Merck & Co., Inc. | Stabilizers for lyophilized mumps vaccines |
US6290967B1 (en) | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
AU725231B2 (en) | 1996-12-20 | 2000-10-12 | Merck & Co., Inc. | Stabilisers for lyophilised vaccines |
US6565831B1 (en) | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
CN100374551C (zh) | 1998-02-17 | 2008-03-12 | 先灵公司 | 含有病毒的组合物以及浓缩病毒制剂的方法 |
GB9808922D0 (en) | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
KR100688434B1 (ko) | 1998-07-28 | 2007-03-09 | 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 다가의 인간-소의 로타바이러스 백신 |
CN1062770C (zh) * | 1998-11-12 | 2001-03-07 | 卫生部长春生物制品研究所 | 甲肝-麻疹二联疫苗及其生产方法 |
DE69940354D1 (de) | 1998-11-16 | 2009-03-12 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
JP4932086B2 (ja) | 1999-04-08 | 2012-05-16 | インターセル ユーエスエイ、インコーポレイテッド | 経皮的免疫のための乾燥製剤 |
US6592869B2 (en) | 1999-08-24 | 2003-07-15 | Teva Pharmaceutical Industries, Ltd. | Vaccine composition and method of using the same |
HUP0202537A3 (en) | 1999-08-24 | 2004-05-28 | Teva Pharma | A vaccine composition and method of using the same |
ATE313318T1 (de) | 1999-10-29 | 2006-01-15 | Nektar Therapeutics | Trockenpulverzusammensetzungen mit verbesserter dispersität |
EP2420247A1 (en) * | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
US7456009B2 (en) * | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
US20020120228A1 (en) | 2000-06-08 | 2002-08-29 | Yuh-Fun Maa | Powder compositions |
EP1289494A2 (en) | 2000-06-08 | 2003-03-12 | Powderject Vaccines, Inc. | Powder compositions |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
TWI289158B (en) | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
GB0020089D0 (en) | 2000-08-15 | 2000-10-04 | Smithkline Beecham Biolog | Vaccine Composition |
KR100927517B1 (ko) | 2000-09-25 | 2009-11-17 | 폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 | 생균 백신 |
US20040033239A1 (en) | 2001-03-06 | 2004-02-19 | Evans Robert K | Adenovirus formulations |
BR0207527A (pt) | 2001-03-16 | 2004-02-25 | Oncolytics Biotech Inc | Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso |
EP1399131A2 (en) | 2001-06-08 | 2004-03-24 | Powderject Vaccines, Inc. | Spray freeze-dried compositions |
GB0124710D0 (en) | 2001-10-15 | 2001-12-05 | Quadrant Healthcare Uk Ltd | Therapeutic composition |
AU2002366267B2 (en) | 2001-11-19 | 2007-05-10 | Becton, Dickinson And Company | Pharmaceutical compositions in particulate form |
CA2469491A1 (en) | 2001-12-12 | 2003-06-19 | Kerrie Setiawan | Composition for viral preservation |
US20030153065A1 (en) | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
US20030232018A1 (en) * | 2002-01-18 | 2003-12-18 | Berlex Biosciences | Stabilized formulations of adenovirus |
WO2003086443A1 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
AU2003234090A1 (en) | 2002-04-11 | 2003-10-27 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for pulmonary administration |
JP4902103B2 (ja) | 2002-04-11 | 2012-03-21 | メディミューン・エルエルシー | 凍結乾燥フォームによる生物活性材料の保存 |
CA2482512C (en) | 2002-04-30 | 2011-09-20 | Oncolytics Biotech Inc. | Improved viral purification methods |
BR0315767A (pt) | 2002-11-01 | 2005-09-06 | Glaxosmithkline Biolog Sa | Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador |
US6752740B2 (en) | 2002-11-12 | 2004-06-22 | Jeffery T. Semmes | Continuously variable transmission |
KR20050088175A (ko) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | 생물활성 물질의 고압 분무 건조 |
US6931888B2 (en) | 2003-02-07 | 2005-08-23 | Ferro Corporation | Lyophilization method and apparatus for producing particles |
CA2522379C (en) | 2003-04-10 | 2012-10-23 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
JP5588586B2 (ja) | 2003-09-02 | 2014-09-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
WO2005052116A2 (en) | 2003-11-19 | 2005-06-09 | Merck & Co., Inc. | Preservative-containing virus formulations |
ES2536322T3 (es) | 2003-12-17 | 2015-05-22 | Wyeth Llc | Procedimiento para producir composiciones de VSR estables en almacenamiento |
WO2005066333A1 (en) | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
GB0404586D0 (en) | 2004-03-01 | 2004-04-07 | Britannia Pharmaceuticals Ltd | Improvements in or relating to organic materials |
AU2005225000A1 (en) | 2004-03-04 | 2005-09-29 | Wyeth | Lyophilization method to improve excipient crystallization |
ES2644416T3 (es) | 2004-06-02 | 2017-11-28 | Universal Stabilization Technologies, Inc. | Conservación mediante vaporización |
WO2006029467A1 (en) | 2004-09-16 | 2006-03-23 | Btf Pty Ltd | Rapid freeze drying process |
US20060067943A1 (en) | 2004-09-28 | 2006-03-30 | Yuh-Fun Maa | Stabilization of alum-adjuvanted immunologically active agents |
CN102302773B (zh) * | 2004-10-06 | 2014-05-14 | 米迪缪尼有限公司 | 冷藏温度稳定的流感疫苗组合物 |
US7901921B2 (en) | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
MX2007005379A (es) * | 2004-11-05 | 2007-07-04 | Wellstat Biologics Corp | Formulaciones de virus envueltos estables y filtrables. |
EP1833385B1 (en) | 2004-12-09 | 2008-08-27 | Precimed S.A. | Surgical tool holder for facilitated sterilization |
US20060141483A1 (en) * | 2004-12-23 | 2006-06-29 | Calton Gary J | Stabilization of viral compositions |
EP2301531B1 (en) * | 2005-02-18 | 2018-06-06 | Abraxis BioScience, LLC | Combinations and modes of administration of therapeutic agents and combination therapy |
CN101312742B (zh) * | 2005-09-16 | 2012-07-25 | 梅瑞尔有限公司 | 用于冷冻干燥的疫苗的稳定剂 |
CN1765181A (zh) * | 2005-10-19 | 2006-05-03 | 路兴波 | 高效抗病毒制剂 |
SI2007883T1 (sl) | 2006-04-20 | 2012-02-29 | Wyeth Llc | Procesi äśiĺ äśenja za osamitev preäśiĺ äśenega virusa vezikularnega stomatitisa iz celiäśne kulture |
JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
EP1854478A1 (en) | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
EP1878791A1 (en) | 2006-07-11 | 2008-01-16 | Bia Separations D.O.O. | Method for influenza virus purification |
EP2055311B1 (en) | 2006-08-07 | 2017-06-21 | The Chemo-Sero-Therapeutic Research Institute | Process for preparing live smallpox vaccine |
KR20090060453A (ko) | 2006-09-25 | 2009-06-12 | 메디뮨 엘엘씨 | 안정화된 항체 제제 및 그것의 용도 |
AU2007317347B2 (en) | 2006-11-03 | 2014-02-06 | Alphavax, Inc. | Alphavirus and alphavirus replicon particle formulations and methods |
WO2008057550A2 (en) * | 2006-11-07 | 2008-05-15 | Sanofi Pasteur Biologics Co. | Stabilization of vaccines by lyophilization |
PL3300743T3 (pl) * | 2006-12-27 | 2023-09-11 | Zoetis Services Llc | Sposoby podawania szczepionki |
WO2008106646A2 (en) | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
KR101647843B1 (ko) * | 2007-03-12 | 2016-08-11 | 온콜리틱스 바이오테크 인코포레이티드 | 변형된 서열을 갖는 레오바이러스 |
GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
EP2131857B1 (en) | 2007-03-22 | 2015-07-29 | The Regents of the University of Colorado, a body corporate | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
KR20170038110A (ko) | 2007-04-06 | 2017-04-05 | 다케다 백신즈 인코포레이티드 | 살아있는 약독화된 바이러스를 위한 방법 및 조성물 |
TW200909581A (en) | 2007-05-21 | 2009-03-01 | Oncolytics Biotech Inc | Mutant reoviruses and methods of making and using |
WO2009042202A2 (en) | 2007-09-25 | 2009-04-02 | Aridis Pharmaceuticals | Formulations for preservation of rota virus |
US10736848B2 (en) * | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
WO2009056651A1 (en) | 2007-11-02 | 2009-05-07 | Cytos Biotechnology Ag | Angiotensin-carrier formulation |
KR20100097691A (ko) | 2007-11-12 | 2010-09-03 | 테라클론 사이언시스, 아이엔씨. | 인플루엔자의 치료 및 진단을 위한 조성물 및 방법 |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
BRPI0908861A2 (pt) | 2008-02-25 | 2018-02-06 | Novavax Inc | partículas semelhantes a vírus de açucar vitrificado (vlps) |
WO2009133413A1 (en) | 2008-04-28 | 2009-11-05 | Novatech D.O.O. | Formulation based on micronized clinoptilolite as a therapeutic agent for removal of toxins, bacteria and viruses from organism |
WO2011026948A1 (en) * | 2009-09-03 | 2011-03-10 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
SG190419A1 (en) * | 2010-12-02 | 2013-06-28 | Oncolytics Biotech Inc | Lyophilized viral formulations |
AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
MX337348B (es) * | 2011-04-29 | 2016-02-29 | Oncolytics Biotech Inc | Metodos para purificar virus utilizando cromatografia de permeacion en gel. |
JP6065096B2 (ja) | 2015-12-25 | 2017-01-25 | ダイキン工業株式会社 | 調湿装置 |
-
2011
- 2011-12-02 AU AU2011336413A patent/AU2011336413B2/en active Active
- 2011-12-02 SG SG2013040803A patent/SG190418A1/en unknown
- 2011-12-02 CN CN201180066706.2A patent/CN103347535B/zh active Active
- 2011-12-02 WO PCT/US2011/063040 patent/WO2012075379A2/en active Application Filing
- 2011-12-02 EP EP11844824.0A patent/EP2646051A4/en not_active Ceased
- 2011-12-02 TW TW100144333A patent/TW201233802A/zh unknown
- 2011-12-02 MX MX2013006170A patent/MX350932B/es active IP Right Grant
- 2011-12-02 KR KR1020137016881A patent/KR101875245B1/ko active IP Right Grant
- 2011-12-02 EA EA201390810A patent/EA201390810A1/ru unknown
- 2011-12-02 US US13/309,966 patent/US9045728B2/en active Active
- 2011-12-02 CA CA2819246A patent/CA2819246C/en active Active
- 2011-12-02 JP JP2013542200A patent/JP6034798B2/ja active Active
-
2013
- 2013-05-29 IL IL226647A patent/IL226647A/en active IP Right Grant
-
2015
- 2015-04-23 US US14/693,977 patent/US9610309B2/en active Active
-
2016
- 2016-09-01 JP JP2016170630A patent/JP6639359B2/ja active Active
-
2018
- 2018-04-10 JP JP2018075352A patent/JP2018123155A/ja not_active Withdrawn
-
2019
- 2019-11-05 JP JP2019200490A patent/JP2020015770A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2016199592A (ja) | 2016-12-01 |
JP6034798B2 (ja) | 2016-11-30 |
MX350932B (es) | 2017-09-26 |
AU2011336413B2 (en) | 2015-01-22 |
CA2819246C (en) | 2023-04-25 |
JP2014502275A (ja) | 2014-01-30 |
IL226647A (en) | 2017-07-31 |
WO2012075379A2 (en) | 2012-06-07 |
EA201390810A1 (ru) | 2013-09-30 |
KR20130121899A (ko) | 2013-11-06 |
EP2646051A2 (en) | 2013-10-09 |
KR101875245B1 (ko) | 2018-08-02 |
CA2819246A1 (en) | 2012-06-07 |
SG190418A1 (en) | 2013-07-31 |
US20120141421A1 (en) | 2012-06-07 |
CN103347535B (zh) | 2015-11-25 |
US9610309B2 (en) | 2017-04-04 |
JP6639359B2 (ja) | 2020-02-05 |
TW201233802A (en) | 2012-08-16 |
JP2020015770A (ja) | 2020-01-30 |
CN103347535A (zh) | 2013-10-09 |
US9045728B2 (en) | 2015-06-02 |
US20150224155A1 (en) | 2015-08-13 |
WO2012075379A3 (en) | 2012-08-16 |
EP2646051A4 (en) | 2014-05-28 |
JP2018123155A (ja) | 2018-08-09 |
AU2011336413A1 (en) | 2013-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013006170A (es) | Formulaciones virales liquidas. | |
MX349294B (es) | Formulaciones virales liofilizadas. | |
CY1119284T1 (el) | ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs) | |
MX2021006342A (es) | Mutantes de virus de influenza y usos para los mismos. | |
MX337936B (es) | Compuestos inhibidores del virus de la hepatitis c. | |
IN2014MN01548A (es) | ||
MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
TN2012000264A1 (en) | Hepatitis c virus inhibitors | |
MX2011008045A (es) | Inhibidores del virus de la hepatitis c. | |
MX2013006475A (es) | Inhibidores macrociclicos de virus flaviviridae. | |
SA515360198B1 (ar) | لقاحات غمس الوحدات الفرعية للسمك | |
MX2009009473A (es) | Compuestos para el tratamiento de hepatitis c. | |
PH12016500500A1 (en) | A viral vaccine and methods of manufacture thereof | |
UA118542C2 (uk) | Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197 | |
MX2013003245A (es) | Vacuna contra virus de diarrea viral de bovinos. | |
GB201008123D0 (en) | Novel compounds | |
MA35303B1 (fr) | Vaccin contre la rhinite equine | |
WO2014008475A3 (en) | Compositions and methods related to viral vaccines | |
MX2012002702A (es) | Vacuna de herpesvirus bovino. | |
WO2013029033A3 (en) | Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures | |
UA113048C2 (xx) | Противірусні сполуки | |
TN2013000453A1 (en) | Hepatitis c virus inhibitors | |
UA108904C2 (xx) | Противірусні сполуки | |
UA108671C2 (xx) | Інгібітори вірусу гепатиту с |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |